Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948364 | 1.00 | MAOB (0.41) | MAOBBACE1APPPDK2SIGMAR1 | |
| SCHEMBL9948266 | 0.87 | BACE1 (0.53) | BACE1APP | |
| SCHEMBL9948269 | 0.87 | BACE1 (0.53) | BACE1APP | |
| SCHEMBL9948033 | 0.86 | MAOB (0.45) | MAOBBACE1APPACACBOPRM1 | |
| SCHEMBL9948622 | 0.86 | BACE1 (0.38) | MAOBBACE1APPPDK2 | |
| SCHEMBL7893883 | 0.83 | OPRM1 (0.41) | BACE1OPRM1 | |
| SCHEMBL7887635 | 0.82 | BACE1 (0.51) | BACE1SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL9947994 | 0.79 | BACE1 (0.50) | BACE1APPPDK2SIGMAR1ACACB | |
| SCHEMBL9947992 | 0.79 | BACE1 (0.50) | BACE1APPPDK2SIGMAR1ACACB | |
| SCHEMBL20451538 | 0.79 | MAOA (0.49) | MAOBBACE1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| EP-3176172-A1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2655378-B1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | disclosed |
| US-9248129-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | US | disclosed |
| US-9000182-B2 | 2H-imidazol-4-amine compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2015-04-07 | — | — | US | disclosed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | disclosed |
| US-20130345246-A1 | 2H-Imidazol-4-Amine Compounds and Their Use as Bace Inhibitors | ASTRAZENECA AB (SE) | 2013-12-26 | — | — | US | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-20130345246-A1 | 2H-Imidazol-4-Amine Compounds and Their Use as Bace Inhibitors | BACE1, BACE2, PSEN2 | MAOB 127/4885BACE1 1/4885APP 5/4885 |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOB 75/4885BACE1 1/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.